Bafna Pharmaceuticals Limited (BAFNAPHARM)
MSE Summary
BAFNAPHARM Chart
Bafna Pharmaceuticals Limited (BAFNAPHARM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Bafna Pharmaceuticals Limited ever had a stock split?
Bafna Pharmaceuticals Limited Profile
| Specialty Retail Industry | Consumer Discretionary Sector | - CEO | MSE Exchange | INE878I01022 ISIN |
| India Country | 588 Employees | - Last Dividend | 26 Aug 2019 Last Split | - IPO Date |
Overview
Bafna Pharmaceuticals Limited is a seasoned player in the pharmaceutical sector, having been founded in 1981 and establishing its headquarters in Chennai, India. This company has carved out a niche for itself in the production and selling of finished pharmaceutical formulations within the Indian market. Its expertise extends to developing a variety of specialized dosage forms, including delayed and sustained release, chewable, and orally disintegrating tablets, catering to a broad spectrum of healthcare needs. Beyond its domestic operations, Bafna Pharmaceuticals Limited has also made a significant mark on the international stage, exporting its products to meet global demand. The company's growth and expansion into new markets are supported by its affiliation as a subsidiary of SRJR Lifesciences LLP, enabling it to leverage synergies and foster innovation in its product offerings.
Products and Services
- Delayed and Sustained Release Tablets
- Chewable Tablets
- Orally Disintegrating Tablets (ODTs)
Bafna Pharmaceuticals excels in the formulation of delayed and sustained release tablets, designed to release medication into the body at a slower, more controlled rate. This technology ensures a prolonged therapeutic effect and improved patient compliance, especially beneficial for treatments requiring consistent blood levels over extended periods.
Understanding the need for easier administration of medication, the company offers chewable tablets. These are particularly advantageous for children and adults who find swallowing pills challenging. Chewable tablets provide a convenient and palatable option, making them a popular choice among various patient demographics.
Bafna Pharmaceuticals also specializes in the production of orally disintegrating tablets, which dissolve or disintegrate in the mouth without the need for water. ODTs offer an essential benefit for patients who experience difficulty swallowing traditional tablets or capsules, enhancing the ease of medication intake and encouraging adherence to treatment regimens.
